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Summary
Acute spinal cord injury (SCI) produces tissue damage
that continues to evolve days and weeks after the initial
insult, with corresponding functional impairments.
Reducing the extent of progressive tissue loss (`neuro-
protection') following SCI should result in a better
recovery from SCI, but treatment options have thus far
been limited. In this study, we have tested the ef®cacy
of minocycline in ameliorating damage following acute
SCI in mice. This semi-synthetic tetracycline antibiotic
has been reported to inhibit the expression and activity
of several mediators of tissue injury, including in¯am-
matory cytokines, free radicals and matrix metallo-
proteinases, making it a suitable candidate for study.
Mice were subjected to extradural compression of the
spinal cord using a modi®ed aneurysm clip, following
which they received treatment with either minocycline
or vehicle beginning 1 h after injury. Behavioural test-
ing of hindlimb function was initiated 3 days after
injury using the Basso Beattie Bresnahan locomotor rat-
ing scale, and at 1 week using the inclined plane test.
Functional assessments demonstrated that minocycline
administration signi®cantly improved both hindlimb
function and strength from 3 to 28 days after injury
compared with vehicle controls. Furthermore, gross
lesion size in the spinal cord was signi®cantly reduced
by minocycline, and there was evidence of axonal spar-
ing as determined using ¯uorogold labelling of the
rubrospinal tract and by Bielchowsky silver stain.
Finally, a comparison of minocycline against the cur-
rently approved treatment for acute SCI in humans,
methylprednisolone, demonstrated superior behavioural
recovery in the minocycline-treated animals.
Keywords: in¯ammation; minocycline; neuroprotection; recovery; spinal cord injury
Abbreviations: MMP = matrix metalloproteinase; NO = nitric oxide; SCI = spinal cord injury
Introduction
Spinal cord injury (SCI) is a leading cause of permanent
disability in young adults (Sekhon and Fehlings, 2001).
Current treatment options for signi®cant recovery from SCI
are limited. The steroid methylprednisolone has been used to
reduce swelling and decrease in¯ammation (Chikawa et al.,
2001; Hall, 2001), but its ef®cacy is controversial as data
from some clinical trials has failed to demonstrate de®nitive
favourable effects (Hurlbert, 2000; Bracken, 2002). Current
long-term treatment strategies in SCI are limited to
rehabilitative physiotherapy in the hope of restoring function,
but the bene®t of this is often minimal and highly variable.
Permanent disability in spinal cord trauma results from
disruption of white matter tracts, death of oligodendrocytes
and extensive neuronal and axonal loss. Approaches to treat
SCI include prevention of tissue loss (neuroprotection) and
regeneration of damaged structures. The bulk of tissue
destruction develops over days to weeks after the insult,
thereby providing a temporal window of opportunity to limit
the spread of damage. Another impetus for neuroprotection is
that the rescue of as few as 10% of spinal cord axons can be
equated with signi®cant functional recovery (Blight, 1983;
Fehlings and Tator, 1995).
Speci®c molecules have been identi®ed that contribute to
cell death following SCI. Over-stimulation of glutamate
receptors (Liu et al., 1991), resulting in a high in¯ux of
calcium ions into the cell, activates a variety of proteases,
caspases, phospholipases and endonucleases that promote
breakdown of cell constituents including plasma membrane.
In¯ammation and the elevation of cytokines (Dusart and
Schwab, 1994) and matrix metalloproteinases (MMPs)
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 (Wang et al., 2000) also accounts for tissue vulnerability in
SCI. Generation of free radicals, including nitric oxide (NO),
likewise plays a signi®cant role in mediating cell death
(Diaz-Ruiz et al., 2002). Many previous treatment strategies
have targeted individual components or mechanisms in cell
injury, and these have proven to be largely unsuccessful when
advanced to clinical trials. It is likely that a more effective
approach to alleviating SCI will be one that acts simultan-
eously on the many mechanisms involved in cell injury and
death.
Minocycline is a synthetic tetracycline derivative that is
used clinically as an antimicrobial agent for the treatment of
conditions such as acne. In recent years, it has been shown to
have many other actions including the inhibition of caspase-1
and caspase-3 (Chen et al., 2000), which are involved in the
generation of interleukin-1 and apoptosis, respectively.
Minocycline also inhibits inducible nitric oxide synthase
that produces NO (Amin et al., 1996) and attenuates the
activation of microglia (Yrjanheikki et al., 1999). A signi®-
cant literature indicates that minocycline inhibits MMPs,
which have many detrimental roles in the CNS (Yong et al.,
2001). In culture, minocycline protects neurons from
glutamate excitotoxicity (Tikka et al., 2001). Thus, minocy-
cline may serve as a multifaceted agent that targets the
multiple processes involved in mediating cell death and the
development of secondary injury in SCI. The aim of this
study was to determine the effect of minocycline following
SCI in mice.
Material and methods
Surgery and housing
Male CD-1 mice (Charles River Laboratories, Montreal,
Quebec, Canada) of approximately 3 months of age were
used. Animals were anaesthetized with a mixture of ketamine
(200 mg/kg) and xylazine (10 mg/kg) injected intraperitone-
ally and immobilized in a stereotactic apparatus. An incision
was made in the skin, and the muscle and the tissue overlying
the spinal column was blunt dissected away revealing the
laminae. Using the spiny process of T2 as a landmark,
laminae 3 and 4 were carefully removed to expose the spinal
cord. Extradural compression of the spinal cord at the
vertebral level of T3/4 was achieved using a modi®ed
aneurysm clip (Joshi and Fehlings, 2002a) with a closing
force of 8 g producing mechanical trauma. The clip was left in
place for 1 min and then removed. The incision was closed in
two layers using nylon suture and the mice were given a
subcutaneous injection of 0.5 ml saline to compensate for any
blood loss during surgery. All experiments were carried out in
accordance with Canadian Council of Animal Care (CCAC)
guidelines and approved by the University of Calgary Ethics
Committee.
In initial experiments, mice were housed in a room where
the ambient temperature was set by a thermostat to 22°C.
However, there were unregulated changes in ambient
temperature resulting from drafts when doors were opened,
etc., and this therefore became effectively a non-temperature
controlled environment. These animals were also heated
using overhead lamps until recovery from surgical anaesthe-
sia was complete. Because of the high mortality (see Results)
of mice in the non-temperature controlled environment,
subsequent experiments utilized animals that were housed in
a warm room maintained at 27°C constantly throughout the
survival period (henceforth, this is referred to as a tempera-
ture controlled environment).
Post-operative care procedures involved providing the
mice with drinking water in the cage as well as both softened
rat chow and regular pellets placed directly in the cage.
Manual expression of the bladder was also required twice
daily. In total, 124 mice were used. Of these, 51 animals were
kept throughout the survival period in the non-temperature
controlled environment, and 73 in the temperature controlled
environment.
Pharmacological treatment of animals
Beginning 1 h after injury, mice in both temperature
environments were given either an intraperitoneal injection
of saline (n = 41) or 50 mg/kg minocycline (n = 43; Sigma, St
Louis, MO, USA). This dose is comparable with that used in
the experimental literature (Yrjanheikki et al., 1999; Sanchez
Mejia et al., 2001; Brundula et al., 2002). This was followed
24 h later by a second injection of 50 mg/kg. Subsequently,
treated mice were injected with a 25 mg/kg dose every 24 h
for the next 5 days. All animals were killed at day 28
following SCI. While mice in the non-temperature controlled
environment were used for mortality studies, animals in the
temperature controlled environment were subjected to
behavioural testing for all mice, while a subset of the animals
were used for ¯uorogold and other histological analyses.
The route of intraperitoneal administration for minocycline
was chosen for two reasons. First, in the case of acute SCI in
humans the incidence of paralytic ileus is quite common and
often lasts for several days (Greenberg, 1997). Post-traumatic
care often involves the insertion of a naso-gastric tube with
frequent suctioning to prevent aspiration of ¯uids into the
lungs (Wilberger, 1996). In this case oral administration of
both food and medications is contra-indicated (Wilberger,
1996; Greenberg, 1997). Secondly, most of the experimental
literature involving minocycline treatment in neurological
diseases cites intraperitoneal injections as the route of
administration (Yrjanheikki et al., 1999; He et al., 2001;
Arvin et al., 2002; Wu et al., 2002; Zhu et al., 2002).
In a second series of experiments focused only on
behavioural recovery, minocycline was tested against
methylprednisolone. Groups (n = 10 each) consisted of mino-
cycline treatment using the above dosing regimen, vehicle
treatment (as above), vehicle (pH 5.0) treatment to mimic the
pH of the minocycline solution and a methyprednisolone
treatment group. Methyprednisolone (30 mg/kg, intramuscu-
larly; Solu-Medrol; Pharmacia Upjohn, Kalamazoo, MI,
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 USA) was administered beginning 1 h after surgery and
repeated every 6 h for 24 h, for a total of ®ve injections/
mouse. This dosing paradigm has been demonstrated to
improve directed forepaw reaching in rats with lesions of the
dorsal corticospinal tract (Nash et al., 2002).
Behavioural assessments
Basso Beattie Bresnahan locomotor rating scale
Beginning 5 days prior to SCI, animals were acclimated in an
open ®eld arena for behavioural testing. Mice were exposed
to the open ®eld every day for 5 days. Sessions were 5 min in
duration. This procedure was important for minimizing fear
and stress within the animals that could negatively in¯uence
behaviour during the test sessions.
Three days following SCI, mice were again placed in the
open ®eld environment where hindlimb function could be
assessed using the Basso Beattie Bresnahan locomotor rating
scale (Basso et al., 1995). This is a 22-point scale that
systematically details hindlimb function of joint movements,
stepping ability, the degree of ®ne control of coordinated
stepping and trunk stability. Test sessions were 4 min in
duration and mice were tested twice weekly, from days 3 to
28 post-injury.
Inclined plane task
Spinal cord injured mice were also tested using a second
behavioural task, the inclined plane, which assesses an
animal's ability to maintain its position on a board which is
raised in 5° increments and thus can be used as an index of
hindlimb strength (Fehlings and Tator, 1992). The maximum
angle at which a mouse is able to maintain its position for at
least 5 s constitutes the inclined plane score. Mice were tested
once a week throughout the survival period beginning at day
7 post-surgery.
Histological analysis of tissue injury
Retrograde labelling with ¯uorogold was used to determine
the degree of axonal integrity through the lesion site (Joshi
and Fehlings, 2002b). Twenty-eight days after injury,
minocycline- (n = 11) and vehicle-treated mice (n =8 )
were subjected to transection surgery at T8 and gelfoam
soaked in 2% ¯uorogold was placed at the site. Two days
later, animals were perfused with 10% neutral buffered
formalin and brains were embedded in paraf®n. Sections
(6 mm) were cut and ¯uorogold-positive cells in both red
nuclei were counted blind.
Histological analysis was also carried out on spinal cord
specimens. Brie¯y, 6-mm thick longitudinal sections from
minocycline (n = 6) and vehicle (n = 5) treated mice were
stained with haematoxylin and eosin. Lesion areas from
sections containing the central canal were outlined using
Image Pro software and lesion size calculated for statistical
analysis. In addition, serial sections were processed with
Bielchowsky silver stain to identify axons. Qualitative
analysis of axonal integrity was determined for both
minocycline and vehicle-treated groups.
Results
Minocycline decreases the mortality of mice recuperating
from SCI in a non-temperature controlled environment
Initial experiments where mice were kept in a non-
temperature controlled environment found a signi®cant
mortality rate in vehicle-treated animals after SCI (Fig. 1).
This was likely the result of the mice being unable to maintain
normal body temperature as the ambient temperature ¯uctu-
ates, and was supported by the ®nding that many saline-
treated animals appeared to be lethargic and exhibited signs
of poor grooming and weight loss. Thus, we evaluated the
ability of minocycline to in¯uence the survival of animals
subjected to SCI. We found that minocycline treatment
signi®cantly attenuated mortality (Fig. 1). Over a 3 week
post-injury period, 16 out of 26 animals (61.5%) from the
vehicle-treated group died, compared with only ®ve of 25
(20%) mice from the minocycline-treated group.
These data indicate that minocycline provides protection
against mortality in spinal cord injured mice and thus may
ameliorate damage evolving from spinal cord compression.
Minocycline improves behavioural scores
following SCI
All subsequent experiments were done on mice housed in a
room maintained constantly at 27°C; herein, the mortality
rate was low and was not different between the minocycline
and vehicle groups.
Behavioural assessments of hindlimb function were con-
ducted twice weekly throughout the experiment using the
Basso Beattie Bresnahan locomotor rating scale. Repeated
measures analysis revealed a signi®cant treatment effect (F =
18.283, P = 0.0002) and a day effect (F = 22.404, P < 0.0001),
as well as a signi®cant treatment by day interaction (F =
2.345, P = 0.0251) where minocycline-treated animals
exhibited signi®cant recovery in hindlimb function compared
with vehicle-treated mice (Fig. 2A). This difference was
observed as early as day 3 post-injury, when minocycline
animals exhibited an average score of 5 compared with an
average score of 2 for control mice (P < 0.005). Some
improvements were noted in the vehicle-treated mice over the
next week, which then plateaued; however, minocycline-
treated mice continued to show improvements in hindlimb
function throughout the survival period. Minocycline-treated
mice achieved a ®nal average score of 10 (indicative of
weight supported plantar stepping) at 4 weeks post-injury
compared with only 4.5 (indicative of slight movements
of hip, knee and ankle joints) for the vehicle-treated group
(P < 0.005). These differences in hindlimb function can be
1630 J. E. A. Wells et al.
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 seen in Fig. 3. Moreover, we found that over half of the
animals that received minocycline had scores >10, indicating
consistent stepping patterns as well as displaying some
evidence of forelimb±hindlimb co-ordination.
The results generated from inclined plane testing, assessing
hindlimb strength, also demonstrated a protective effect with
minocycline treatment (F = 5.878, P = 0.0249). Mice treated
with this compound exhibited signi®cantly higher scores than
vehicle-treated mice at weeks 3 and 4 post-injury (P < 0.05,
Fig. 2B). Furthermore, there was a signi®cant correlation
between Basso Beattie Bresnahan score and inclined plane
score over all test days (r = 0.70, P < 0.0001).
Minocycline confers neuroprotection in SCI
The functional protection observed in minocycline-treated
animals may be due, in part, to tissue sparing, especially since
a difference from saline-treated mice was observable by 3
days post-injury. Retrograde labelling of red nucleus neurons
(Fig. 4A) indicated that there was a trend towards a greater
preservation of the rubrospinal tract in minocycline-treated
mice compared with vehicle controls (Fig. 4B). Furthermore,
there was a signi®cant correlation between Basso Beattie
Bresnahan score at day 28 and neuronal soma counts in the
red nucleus (r = 0.84, P < 0.0001) (Fig. 4C). Finally,
preservation of axonal integrity was veri®ed in spinal cord by
histological criteria. The analysis of spinal cords from vehicle
(n = 5) and minocycline (n = 6) treated mice stained with
Bielchowsky silver stain, a speci®c stain for axons, indicated
that there were qualitatively more intact axons in minocy-
cline-treated animals compared with vehicle-treated controls
(Fig. 5).
The trend towards preservation of rubrospinal neurons and
of Bielchowsky axonal pro®les indicates that minocycline
may have a more global neuroprotective effect on spinal cord
tissue including non-axonal elements. Thus, of note,
haematoxylin and eosin-stained tissue revealed a signi®cant
reduction in lesion size in minocycline-treated mice com-
pared with vehicle-treated controls (1.76 versus 2.80 mm2,
respectively; P < 0.001; see Fig. 6).
Fig. 2 Minocycline improves Basso Beattie Bresnahan and
inclined plane scores. (A) Recovery of hindlimb function
following SCI was assessed using the Basso Beattie Bresnahan
locomotor rating scale. The data indicate that minocycline-treated
mice exhibit signi®cantly higher scores (*P < 0.005, unpaired
t-test with P-value corrected for multiple comparisons) on each
test day. Furthermore, minocycline-treated mice demonstrate
continued improvements in hindlimb function reaching a ®nal
score of 10, which indicates weight supported plantar stepping.
(B) Hindlimb strength was assessed using the inclined plane test.
While both groups demonstrated improvements in hindlimb
strength with increasing survival time, animals in the minocycline-
treated group tended to have higher scores and were signi®cantly
different from vehicle-treated controls on days 21 and 28 post-SCI
(*P < 0.05, unpaired t-test with P-value adjusted for multiple
comparisons). The group size was 18 mice in the minocycline
group and 15 in the vehicle cohort.
Fig. 1 Minocycline improves survival from SCI when animals
were kept in a non-temperature controlled environment. The
incidence of mortality in minocycline-treated SCI mice was
compared with that in vehicle-treated controls over a 3-week
survival period in a non-temperature controlled environment. The
cumulative survival refers to the proportion of mice surviving
from an initial group size of 26 and 25, respectively, following
saline or minocycline treatment. The administration of
minocycline beginning 1 h post-injury and every 24 h for 6 days
thereafter signi®cantly reduced death.
Neuroprotection in spinal cord trauma 1631
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 Minocycline is more effective than
methylprednisolone in facilitating behavioural
recovery
In a ®nal series of experiments, we compared the extent of the
functional recovery elicited by minocycline against methyl-
prednisolone. We also controlled for the possibility that the
pH (5.0) of the minocycline solution might have generated a
stress response, by including a vehicle group where the pH of
the saline solution was lowered to 5.0 with HCl. While
minocycline treatment resulted in signi®cant recovery of
hindlimb function, methylprednisolone injections did not lead
to behavioural improvement compared with saline controls
(Fig. 7). Repeated measures analysis revealed a signi®cant
treatment effect (F = 6.020, P = 0.003) and a day effect (F =
57.362, P < 0.001), as well as a signi®cant treatment by day
interaction (F = 2.169, P = 0.004). Multiple comparison post
hoc analysis using Tukey's uncovered signi®cant differences
between minocycline-treated mice and mice from all other
treatment groups [P-values <0.01, <0.05 and <0.05 for
vehicle, vehicle (pH 5.0) and methylprednisolone, respect-
ively]. Furthermore, the pH 5.0 vehicle group did not differ
from saline controls.
Discussion
Traumatic injury to the spinal cord typically results in axonal
damage and cell death and leaves individuals with varying
degrees of functional impairments. The extent of these
impairments is dependent upon both the severity of the injury
as well as the level at which the injury occurred. Damage
arising from acute SCI is generally described as two distinct
pathophysiological events. The damage incurred at the time
of injury is termed primary injury and typically results from
direct mechanical disruption of cord integrity. In contrast,
secondary injury occurs in a delayed yet progressive fashion
and involves cellular and biochemical events that initiate
cascades culminating in tissue damage and cell death
(Dumont et al., 2001). It is well recognized that the evolution
of secondary tissue damage spreads away from the injury
epicenter, incorporating tissue both rostral and caudal to the
primary lesion with increasing functional de®cits. The fact
that damage continues to develop over time in the days and
weeks following acute SCI provides an opportunity to
intervene. Neuroprotective strategies aimed at preventing
damage arising from secondary injury processes provide
some hope for tissue sparing and improved functional
outcome. This in conjunction with the fact that current
treatment options are limited hastens the need to ®nd novel
therapeutic agents.
In these experiments, we found that minocycline facilitated
signi®cant long-term recovery of mice from SCI. This was
true for both hindlimb function and strength. Three days
following SCI both minocycline- and vehicle-treated mice
exhibited severe de®cits in hindlimb function and locomoted
using forelimbs and dragging hindlimbs. The only observed
Fig. 3 Representative hindlimb movements of mice at 28 days post-injury. (A±C) Non-contiguous sequences demonstrating the extension
of the hindlimbs with little stepping motion typical of vehicle-treated mice. D±F are from a minocycline mouse: (D and E) contiguous
sequences showing stepping of the left hindlimb; (F) is another example of stepping motions.
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 hindlimb movements consisted of slight-extensive move-
ments of the hindlimb joints, with no evidence of weight
support. While both groups showed some improvement
throughout the duration of the study, recovery in the vehicle
group was limited. In contrast, minocycline-treated mice
showed continual and signi®cant improvements over the 4-
week recovery period. Twenty-eight days post-injury the
average group score for the Basso Beattie Bresnahan test was
10, with a majority of mice exhibiting scores >10. In these
animals, consistent weight supported plantar stepping was
observed, and some showed evidence of forelimb±hindlimb
coordination.
Since the functional recovery of minocycline-treated mice
can be differentiated from vehicle controls from the earliest
time point studied (3 days), the mechanism of minocycline is
likely one of neuroprotection, rather than tissue regeneration.
In support, minocycline provided histological savings in
terms of lesion size as well as spared axons. Axonal sparing
was observed qualitatively in tissue sections stained with
Bielchowsky silver stain, as well as inferred from the
¯uorogold counts where only intact axons could transport
this marker through the lesion site. Fluorogold-labelled cells
were counted in the red nucleus, since neurons of the red
nucleus project descending axons to form the rubrospinal
tract. It can be argued that the axonal sparing inferred from
the ¯uorogold data contributed to the improved hindlimb
function seen in the minocycline-treated animals, as the
rubrospinal tract of rodents is heavily involved in motor
function (Muir and Whishaw, 2000; Kuchler et al., 2002). In
keeping with this a strong correlation was demonstrated
between ¯uorogold counts and Basso Beattie Bresnahan
scores 28 days post-SCI (P < 0.0001). Although the
difference between the two groups in terms of cell counts
was not statistically signi®cant, the difference was >10%. As
mentioned previously, the literature indicates that rescue of as
few as 10% of the long ®bre tracts in the spinal cord can be
suf®cient for locomotive ability (Blight, 1983).
The pathophysiological events contributing to SCI are
thought to involve free radical production, lipid peroxidation,
eicosanoid and prostaglandin production, protease activity,
excitotoxic molecules such as glutamate, and intracellular
increases in Ca2+ (Dumont et al., 2001). In addition, several
components of in¯ammation are also thought to be involved
(Bethea, 2000). There is an increasing body of evidence that
minocycline has many other effects independent of its
antimicrobial actions. Many of these actions include the
inhibition of several of the mediators of secondary injury
described above. For example, Yrjanheikki and colleagues
showed that in primary neuron cultures treated with
minocycline, cell death due to glutamate toxicity was
signi®cantly attenuated (Yrjanheikki et al., 1999).
Furthermore, these investigators demonstrated that minocy-
cline was also able to inhibit the induction of interleukin-1-
converting enzyme (caspase-1), and reduce cyclo-oxygenase-
2 expression as well as prostaglandin E2 production in a
model of focal ischaemia in the rat (Yrjanheikki et al., 1999).
Minocycline has also been shown to inhibit the upregulation
of caspase-1 and -3 mRNA expression in a mouse model of
Huntington's disease, as well as to decrease iNOS activity
(Chen et al., 2000). In a recent study, minocycline was
demonstrated to inhibit the release of cytochrome c from
mitochondria, an effect that decreased apoptosis of cells (Zhu
et al., 2002). Finally, minocycline has been reported to reduce
the production of MMPs as well as inhibit their activity
Fig. 4 A trend towards preservation of the rubrospinal tract was
obtained following minocycline treatment compared with vehicle
injections. (A) Representative section of red nucleus labelled with
¯uorogold that was administered distal to the injury in the spinal
cord. (B) Labelled neurons were counted across the entire red
nucleus from minocycline (n = 11) and vehicle (n = 8) treated
mice following retrograde ¯uorogold labelling. Minocycline
treatment preserved some white matter tracts compared with
vehicle, as indicated by a greater number of cells within the red
nuclei that were ¯uorogold positive. However, this did not arrive
at statistical signi®cance (P = 0.09, unpaired t-test). (C)
Correlation analysis between Basso Beattie Bresnahan score on
day 28 post-injury and cell counts from red nuclei. The signi®cant
correlation indicates that axonal sparing through the lesion site is,
in part, responsible for improved hindlimb function in the
minocycline group.
Neuroprotection in spinal cord trauma 1633
b
y
 
g
u
e
s
t
 
o
n
 
O
c
t
o
b
e
r
 
3
1
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 (Paemen et al., 1996; Brundula et al., 2002). Although the
precise molecular mechanisms by which minocycline facili-
tates recovery from SCI remain to be elucidated, it is
tempting to speculate that it simultaneously interferes with
Fig. 5 Axonal tracts through the site of spinal cord compression are relatively preserved following minocycline administration compared
with saline treatment. A and B are higher magni®cation micrographs of the upper area of the spinal cord displayed in C and D,
respectively. These are representative results (from ®ve vehicle and six minocycline mice) of spinal cord processed for Bielchowsky silver
stain demonstrating axons in spinal cords from minocycline (B, D) and vehicle (A, C) treated mice. Qualitatively, there is better
preservation of axonal integrity in the white matter of minocycline-treated mice compared with vehicle controls. Magni®cation C, D 253
and A, B 1003.
Fig. 6 Preservation of spinal cord tissue following minocycline treatment. Histological analyses were conducted of longitudinal sections
encompassing the lesion area and containing the central canal. Lesion areas (A) were outlined using Image Pro software and tabulated. In
correspondence with behavioural indices, minocycline treatment resulted in a signi®cant decrease in lesion area compared with saline-
treated controls (*P < 0.001) (B). There was a signi®cant correlation between lesion size thus analysed and the Basso Beattie Bresnahan
score of 11 mice analysed (C).
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 the in¯ammatory cascades, free radicals, MMPs, glutamate
and other molecules that contribute to primary and secondary
mechanisms of injury. This is unlike conventional therapies
of the past (i.e. glutamate antagonists, gangliosides, Ca2+
channel blockers), which have generally been highly speci®c,
targeting only one element in the cascade. This approach
often leaves other damaging processes intact to mediate
further injury. While animal studies involving these com-
pounds have demonstrated some ef®cacy, they have proven
largely unsuccessful when advanced to clinical trial. To date,
methylprednisolone is the only drug currently approved for
use in the treatment of acute SCI, and only in some centres.
The use of methylprednisolone in acute SCI therapy is highly
controversial due to a lack of conclusive evidence of ef®cacy
from both animals studies and clinical trials (Hurlbert, 2000,
2001; Molano et al., 2002; Rabchevsky et al., 2002; Takami
et al., 2002). When minocycline treatment was compared
with methylprednisolone treatment in this model of spinal
cord compression, functional bene®ts were observed only
after minocycline administration. The dosing regimen used
here is similar to that used by Nash and colleagues, who
demonstrated signi®cantly improved directed forepaw reach-
ing in rats with lesions of the dorsal corticospinal tract (Nash
et al., 2002). Reasons for the difference in the neuroprotective
ef®cacy of methylprednisolone in that study and the results
reported here may include the different species used or the
severity of the injury produced; that is, compression of the
whole cord in this study versus lesion of the dorsal funiculus
(including corticospinal tract) only in the study by Nash et al.
(2002).
Concerns have been raised in the literature regarding the
acidity of the minocyline solutions used parenterally (Nessler
et al., 2002). We controlled for the possibility that the mildly
acidic solution (pH 5.0) of minocycline used intraperitoneally
could have generated discomfort that then evoked physio-
logical changes such as a stress response. In this regard, the
use of saline vehicle with pH 5.0 did not evoke behavioural
recovery from normal saline controls (Fig. 7). Moreover,
inspections of the peritoneal cavity when mice were killed at
the end of the experimental period did not reveal any ®brosis.
Regardless of the ultimate mechanisms of minocycline, a
clinical trial to test the effectiveness of minocycline in
recovery from SCI seems warranted. In this regard,
minocycline has already been demonstrated to have a good
safety record during prolonged use in humans to treat
infections associated with acne (Seukeran et al., 1997;
Shapiro et al., 1997). Moreover, minocycline is small (494
Da protein) and highly lipophilic, so it readily penetrates the
blood±brain barrier to enter the CNS (Saivin and Houin,
1988). Furthermore, the serum levels of minocycline result-
ing from the intraperitoneal injections in mice in this study
(5±10 mg/ml) are comparable to those obtained after oral
dosing of 200 mg in humans (J.Wells, V.Simon, B.Herman,
A.Lyon and V.W.Yong, unpublished results). Another argu-
ment in favour of minocycline treatment for SCI is that this
drug is proving to have widespread ef®cacy in limiting the
pathology of animal models of CNS diseases including
Parkinson's disease (Wu et al., 2002), Huntington's disease
(Chen et al., 2000), stroke (Yrjanheikki et al., 1999), multiple
sclerosis (Brundula et al., 2002; Popovic et al., 2002) and
amyotrophic lateral sclerosis (Zhu et al., 2002).
In summary, we demonstrate that the use of minocycline in
a mouse model of SCI signi®cantly preserves axonal
integrity, prevents tissue loss and leads to behavioural
improvements. While the clinical score of the minocycline-
treated SCI mice is remarkable compared with vehicle
controls, it is possible that further recovery could be
facilitated by rehabilitative treatments such as physiotherapy.
We propose that the current results warrant further investi-
gations to determine whether minocycline may be of bene®t
for the treatment of acute SCI in humans.
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